Buckingham says Watson Pharmaceuticals (WPI -1.3%) remains a Top Pick , given its attractive...
Buckingham says Watson Pharmaceuticals (WPI -1.3%) remains a Top Pick , given its attractive growth profile, Actavis acquisition benefits and continued settlement discussions with Endo (ENDP -0.8%). The firm reiterates its Buy rating with a $100 price target.
From other sites
Video at CNBC.com (May 22, 2015)
Video at CNBC.com (May 11, 2015)
Video at CNBC.com (Apr 9, 2015)
at CNBC.com (Feb 5, 2015)
at CNBC.com (Jan 30, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs